tirzepatide and cancer 💊 Weight-loss drug shows cancer-fighting potential Researchers at the University of Michigan discovered that (Mounjaro, Zepbound), already FDA-approved for diabetes obesity, also shrinks breast tumors in obese mice. When GLP-1s appear to cut cancer

What Are the Benefits of Subcutaneous Injections

These medications markedly reduce appetite and food intake, with patients commonly reporting early satiety and decreased interest in eating

Tyrosine promotes cognitive flexibility: Evidence from proactive vs

FDA submission is likely coming in 2026/2027 if the remaining readouts hold up Some other noteworthy drugs in the pipeline: Tirzepatide: The base drug is already approved for diabetes and obesity, but Lilly keeps expanding its label Kisunla (donanemab) for Alzheimer's Eloralintide: amylin receptor agonist heading to phase 3, at ADA it showed 20% weight loss on the amylin pathway alone MORF-057: bit of a wild card, after the $3.2 billion acquisition of Morphic

Good methylation and adequate folate intake strengthen and regenerate the gut barrier

This ruling puts immense pressure on medspa owners to navigate a complex and shifting regulatory landscapeall while trying to serve their patients